Head-to-head comparisons of medication uses, side effects, warnings, and more.
Farxiga (dapagliflozin)
Wegovy (semaglutide)
Farxiga (dapagliflozin)
Wegovy (semaglutide)
Summary of Farxiga vs. Wegovy
Summary for SGLT2 inhibitor
Prescription only
Farxiga, the brand name for dapagliflozin, is used together with a nutritious diet and exercise plan to lower blood sugar levels in people 10 years and older with Type 2 diabetes. It can also help lower the risk of serious complications, hospitalization, and death in certain adults with heart failure or chronic kidney disease (CKD). Farxiga (dapagliflozin) belongs to the drug class called sodium-glucose cotransporter 2 (SGLT2) inhibitors. It's taken by mouth once a day. Some side effects include yeast infections, urinating more often, and weight loss.
Summary for GLP-1 agonist
Prescription only
Wegovy (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist that's injected under the skin. It's used together with a lower-calorie diet and regular exercise. Wegovy (semaglutide) is approved to help with weight loss in certain adults and children 12 years of age and older. It also helps lower the risk of heart attack, stroke, and death due to heart problems in adults with a larger body size and heart disease. The dosing schedule for the injections is once a week. Common side effects include nausea, diarrhea, and stomach pain.
Indications of Farxiga vs. Wegovy
Indications for
•Type 2 diabetes (in addition to diet and exercise) in people age 10 and over
•Lowering the risk of hospitalization for heart failure in adults with Type 2 diabetes and heart disease
•Lowering the risk of hospitalization and death due to heart problems in people with heart failure
•Lowering the risk of worsening kidney problems, hospitalization for heart failure, and death due to heart problems in adults with chronic kidney disease (CKD)